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Abstract
Background: Walnuts significantly decrease total and low-density lipoprotein cholesterol in normo- and
hypercholesterolemic individuals. No study to date has evaluated the effects of walnuts on cholesterol efflux, the
initial step in reverse cholesterol transport, in macrophage-derived foam cells (MDFC). The present study was
conducted to investigate the mechanisms by which walnut oil affects cholesterol efflux.
Methods: The extract of English walnuts (walnut oil) was dissolved in DMSO and applied to cultured THP-1 MDFC
cells (0.5 mg/mL). THP-1 MDFC also were treated with human sera (10%, v:v) taken from subjects in a walnut
feeding study. Cholesterol efflux was examined by liquid scintillation counting. Changes in gene expression were
quantified by real time PCR.
Results: Walnut oil treatment significantly increased cholesterol efflux through decreasing the expression of the
lipogenic enzyme stearoyl CoA desaturase 1 (SCD1) in MDFC. Alpha-linolenic acid (ALA), the major n-3
polyunsaturated fatty acids found in walnuts, recaptured SCD1 reduction in MDFC, a mechanism mediated through
activation of nuclear receptor farnesoid-X-receptor (FXR). Postprandial serum treatment also increased cholesterol
efflux in MDFC. When categorized by baseline C-reactive protein (CRP; cut point of 2 mg/L), subjects in the lower
CRP sub-group benefited more from dietary intervention, including a more increase in cholesterol efflux, a greater
reduction in SCD1, and a blunted postprandial lipemia.
Conclusion: In conclusion, walnut oil contains bioactive molecules that significantly improve cholesterol efflux in
MDFC. However, the beneficial effects of walnut intake may be reduced by the presence of a pro-inflammatory
state.
Trial Registration: ClinicalTrials.gov: NCT00938340
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Background
Cardiovascular diseases (CVD) are leading causes of
morbidity and mortality worldwide. Atherosclerotic
thrombus rupture is the major underlying pathologic
etiology. To stabilize the arterial plaque and prevent car-
diac events, it is critically important to alleviate the per-
ipheral lipid burden. This can be achieved by lowering
de novo lipogenesis and/or increasing the capacity of
reverse cholesterol transport (RCT), a multi-step process
transporting extrahepatic lipids to the liver for bile acid
secretion.
Numerous studies have shown that nut consumption
favorably affects circulating lipids and lipoproteins with
LDL-cholesterol (LDL-C) being reduced by 3% to 19%
in different populations [1]. While most tree nuts are
rich in MUFA, walnuts contain high levels of PUFA,
both linoleic acid (LA) and alpha-linolenic acid (ALA).
A recent meta-analysis reported that walnut intake con-
sistently reduces total cholesterol and LDL-C in dietary
intervention studies [2]. The hypocholesterolemic effects
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esis due to their high PUFA content [3]. Thus, walnut
PUFA would be predicted to lower the cholesterol bur-
den in atherosclerotic plaques. However, no study to
date has evaluated the effects of walnuts on cholesterol
efflux.
RCT begins with cholesterol export across the cyto-
plasm membrane, a process known as cholesterol
efflux. Our previous study showed that the omega-3
PUFA ALA significantly decreases cholesterol storage
and increases cholesterol efflux in macrophage-derived
foam cells by inhibiting the lipogenic enzyme, stearoyl
CoA desaturase1 (SCD1) through activation of a
nuclear receptor farnesoid-X-receptor (FXR) pathway
[4]. SCD1 is an endoplasmic reticulum enzyme that
converts saturated fatty acids, palmitic acid and stearic
acid, to MUFAs (palmitoleic acid and oleic acid). Rela-
tive to their dietary counterparts, endogenously pro-
duced MUFAs are preferentially incorporated into
triacylglycerols and cholesteryl esters [5]. Due to its
critical role in hepatic de novo lipogenesis, SCD1 has
been proposed as a new drug target for obesity [6] and
metabolic syndrome [7]. Manipulation of SCD1
impacts cholesterol efflux as demonstrated in our pre-
vious study as well as those of others [8]. However,
repressing SCD1 expression by antisense oligonucleo-
tide in atherogenic mouse models showed an inconsis-
tent effect on aorta atherosclerotic plaque formation
[9-13]. Thus, it is not clear whether SCD1 could be a
drug or dietary target to prevent atherosclerosis
progression.
In the present study, we tested the hypothesis that
PUFAs, especially n-3 PUFA ALA rich walnut oil would
favorably affect cholesterol efflux and SCD1 expression
in THP-1 MDFC.
Methods
Chemicals
Human LDL, ciprofibrate, rosiglitazone, TO901317,
GW4064, b-carotene, g-tocopherol, b-sitosterol and free
fatty acids used in the study were purchased from
Sigma-Aldrich; St. Louis, MO. Z-Guggulsterone was
purchased from EMD Chemicals Inc. (Gibbstown, NJ).
GW 501516 and 9-cis retinoic acid (9-cis RA) was pur-
chased from Enzo Life Sciences Inc. (Farmingdale, NY).
Purified apoA-I and HDL were purchased from Calbio-
chem (La Jolla, CA). Rabbit polyclonal anti-SCD1 anti-
body was a kind gift from Dr. Alan R. Tall (Columbia
University). Rabbit polyclonal anti-ACTIN and anti-SHP
antibodies were purchased from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA). [1a,2a (n)-
3H] cholesterol
was purchased from GE Healthcare Bio-Sciences Corp.
(Piscataway, NJ).
Cell culture
THP-1 (Homo sapiens monocyte) and HEK-293 (Homo
sapiens kidney epithelial) cell lines were obtained from
the American Type Culture Collection (ATCC; Rock-
ville, MD). Cell culture conditions are as suggested by
ATCC.
Walnut oil preparation in in vitro studies
English walnuts were provided by the California Walnut
Commission. Shelled whole walnuts were stored at -20 °
C before use. Lipid extraction from de-skinned walnut
meat was done using a modification of the methods
described by Meyer and Terry [14]. The lipid extracts
were weighed and dissolved in DMSO to attain a stock
concentration of 100 mg/mL. The stock solution was
sealed under argon and stored at -20 °C. To minimize
the effect of DMSO on gene expression and to maxi-
mize oil solubility in the medium, we did a 1:200 dilu-
tion of walnut oil stock in the medium to achieve the
highest oil treatment concentration as 0.5 mg/mL
(DMSO as 0.5%, v:v). This concentration did not cause
toxicity as tested by CellTiter Cell Proliferation Assay
(Promega; Madison, MI).
Clinical walnut components acute feeding study
Fifteen subjects with a BMI of 25 to 39 kg/m
2,L D L≥
110 mg/dL and triglycerides (TG) < 350 mg/dL com-
pleted a randomized, controlled, four-period, postpran-
dial feeding study. During each of the four visits to the
General Clinical Research Center, participants consumed
one of the four test diets. The four test diets were ran-
domly provided as 85 g of ground whole walnuts, 34 g
of ground de-fatted walnut meat, 51 g of walnut oil or
5.6 g of ground defatted walnut skins. Gram weights of
meat, skin and oil fractions were derived from 85 g of
whole walnuts. After a baseline blood-draw, participants
consumed one of the four walnut components incorpo-
rated into diet Jell-OTM over a 10 to 15 min period. At
1, 2, 4, 6 h postprandially, whole blood was drawn.
Blood was centrifuged for 15 min to separate sera and
stored at -80 °C before use. In between each of the four
visits, participants had a 3- to 4-week break, during
which they consumed a low antioxidant diet advised by
a dietician. The informed consent was written and
agreed by all participants. The clinical study conformed
to the principles outlined in the Declaration of Helsinki,
and was approved and conducted in accordance with
the guidelines of the Institutional Review Board of The
Pennsylvania State University. The clinical study was
registered at clinicaltrials.gov (Identifier: NCT00938340;
Study title: Postprandial Effects of Walnut Components
Versus Whole Walnuts on Cardiovascular Disease
(CVD) Risk Reduction).
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Page 2 of 13Fatty acid analysis of serum total lipids and HDL
phospholipid fraction
All analyses were performed in Lipoprotein Analysis
Core Laboratory, Section on Lipid Sciences, Wake For-
est University. Samples were saponified in ethanolic
KOH and were acidified by the addition of glacial acetic
acid. The fatty acids liberated from total lipids were
extracted into hexane, which was subsequently evapo-
rated under a stream of nitrogen gas. FAMEs were sepa-
rated and quantified by gas liquid chromatography
(GLC) on a CP Select for FAME capillary column (100
m × 0.25 mm id; Varian, Palo Alto, CA). Each chroma-
togram was examined to verify the identification of con-
stituent fatty acids. The HDL fraction was collected
using an FC 203B Fraction Collector (Gilson Inc.).
Lipids were recovered from the HDL using a modified
Bligh-Dyer chloroform and methanol extraction proce-
dure [15]. The solvents were evaporated under a stream
of nitrogen gas at less than 60°C. The lipid extract was
applied as a thin streak to a thin layer chromatography
(TLC) plate (Whatman Partisil K6 Silica Gel 60). The
silica gel containing the phospholipids (PL) was scraped
off the TLC plate and the fatty acid moieties of the PL
were converted to more volatile FAMEs in situ on the
silica gel by the method of Metcalfe et al [16]. The
FAMEs were extracted into hexane, the solvent evapo-
rated under nitrogen gas at 60°C, dissolved in isooctane,
and then transferred to chromatography vials and
capped. FAMEs were separated and quantified by GLC
as described above.
Cholesterol efflux
THP-1 human monocytes were differentiated into
macrophages by incubating with 100 nM PMA for 48 h
in 24-well plates at a density of 3 × 10
5/well. To induce
foam cell formation and equally label intracellular cho-
lesterol pool, cells were loaded with 50 μg/mL oxLDL
(prepared as described elsewhere [17]) and
3Hc h o l e s -
terol (1 μCi/mL) in normal growth medium. After 24 h,
cells were washed twice and treated with walnut oil or
10% (v:v) human sera from each subject of walnut oil
group at baseline and 4 h postprandially, respectively, in
serum free media. Following a 24-hour treatment, media
were collected and centrifuged at 13,200 × g for 10 min
to remove cell debris. Cells were treated by lysis buffer
(5 mM Tris Cl + 0.1% SDS), and media and intracellular
tritium (dpm) was measured by liquid scintillation
counting.
RNA extraction, reverse transcription, real time PCR
The detailed procedure was as described elsewhere [18].
Primer sequences were listed in Additional file 1, Table
S1 (see supplementary materials online).
Western blot
THP-1-derived macrophages were seeded in 15 cm
2
plates at a density of 5 × 10
6/plate. Following treatment,
cells were treated by lysis buffer as described by Heine-
mann and Ozols [19]. Lysates were sequentially centri-
fuged at 800 × g and 13,200 × g.T h ep r o t e i n
concentration in the final supernatant was measured by
Bio-RAD DC protein assay kit (Bio-RAD Laboratories;
Hercules, CA). Total soluble protein was separated on a
12% SDS-PAGE gel and transferred to a PVDF mem-
brane (Immobilon P; Millipore, Bedford MA). All mem-
branes were blocked by 5% non-fat dry milk in TBS +
0.2% Tween 20 (TBS
+)a t4° Co v e r n i g h t .T h em e m -
brane was incubated with primary antibody (anti-SCD1
1:1000; anti-ACTIN 1:500) at room temperature for 2 h.
To detect SHP, the membrane was incubated with pri-
mary antibody (anti-SHP1 1:200) at 4 °C overnight.
After incubation with primary antibody, the blots were
washed three times with TBS
+ and incubated with
horseradish peroxidase-linked secondary anti-rabbit
antibodies (1:10,000, 1:5,000 and 1:5,000, respectively) at
room temperature for 1 h. Blots were visualized by ECL
plus western blot detection kit (GE Healthcare Bios-
ciences; Piscataway, NJ).
Transfection
Plasmids of human peroxisome proliferator-activated
receptor (PPAR)-a/-b/-g ligand binding domain (LBD),
liver-X-receptor (LXR) LBD, and retinoid-X-receptor
(RXR-a) LBD were constructed as previously described
[20]. Human farnesoid-X-receptor (FXR) and preg-
nane-X-receptor (PXR) LBDs were constructed using
the same methods. Human small heterodimer partner
(SHP) expression plasmid pCMX-hSHP was a kind gift
from Dr. David J. Mangelsdorf (UT Southwestern Med-
ical Center, Dallas). All transfection reactions were
cotransfected with Renilla luciferase plasmid (pRL-TK)
as internal control. HEK293 cells were placed in col-
lagen pre-coated 96-well plate at a density of 2 × 10
4/
well. Each well was transfected with 45 ng cDNA in 30
μL of lipofectamine for 3 h. The well volume was
brought up to 100 uL with growth media. Various
treatments were then added to the cells and incubated
overnight. After 18 to 20 h, the media/treatment was
removed and luciferase activities were determined
using Promega’s Dual Luciferase Assay (Promega;
Madison, MI).
Viral infection
Human SCD1 coding sequence was amplified by PCR
using human HepG2 hepatocyte-derived cDNA as a
template with primers tailed with BamHI and EcoRI
restriction sites. The PCR product was sub-cloned to
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copGFP (System Biosciences; Mountain View, CA).
HEK293 cells were transfected with 5 μgp C D H - h SCD,
2.4 μg pCMV-VSV-G-RSV-Rev, 2.4 μgp C A G - H I V g p ,
and 16.5 μl Lipofectamine in 15 cm
2 plates. After 5 h,
the volume was brought to a total of 10 mL and incu-
bated overnight. The DNA complex was removed the
next day and pseudo viruses were expressed by HEK293
cells and secreted in the growth media. After 72 h,
media was collected, spun, filtered and applied to infect
THP-1 monocyte-derived macrophages with 2 μg/μLo f
polybrene for 24 h.
Statistical analyses
General Linear Model (GLM) ANOVA, followed by
Tukey post-hoc test, was used to test the difference
between treatments (P < 0.05). Normality of the data
was checked by Anderson-Darling test. The values were
expressed as mean ± SEM. All data analyses were per-
formed by Minitab Ver.15 (Minitab Inc., State College,
PA) and data plotted by Prism 5.01 (GraphPad Software,
Inc., San Diego, CA).
Results and Discussion
Walnut oil increases cholesterol efflux and reduces SCD1
expression in THP-1 MDFC
Following walnut oil treatment (0.5 mg/mL), cholesterol
efflux was significantly increased by 35%, compared to
DMSO control treatment (Figure 1A). Genes related to
cholesterol transport and storage were examined follow-
ing exposure of THP-1 foam cells to walnut oil in vitro.
Compared to DMSO, walnut oil treatment (0.25 and 0.5
mg/mL) did not significantly affect the expression of
genes related to membrane transporter (ABCA1,
ABCG1,S C A R B 1 ,CD36, SCARA1), cholesterol storage
(ACAT, CEH)o rs e c r e t i o n( APOE, CYP27A1)( F i g u r e
1B). Among the key enzymes tested in the lipid synth-
esis (FAS, ACC, HMGCR, ELOVL6) and oxidation (CPT,
ACO) pathways, only SCD1 mRNA was significantly
reduced in a dose-dependent manner following walnut
oil treatment (Figure 1C). Concordant with its effects on
transcript levels, SCD1 protein was reduced by approxi-
mately 50% following walnut oil (0.5 mg/mL) treatment
(Figure 1D) without affecting ABCA1 and ABCG1 pro-
teins, two major membrane transporters mediating cho-
lesterol efflux (Figure 1E). To elucidate the role of SCD1
in cholesterol efflux, this protein was overexpressed in
foam cells using lentivirus delivery. Accumulation of
SCD1 protein significantly inhibited cholesterol efflux by
52% in DMSO treated cells (Figure 1F). Walnut oil
treatment could not restore the cholesterol efflux in
cells overexpressing SCD1 (Figure 1F). The regulation of
SCD1 mRNA by walnut oil was tested further by treat-
ment with the predominant saturated, monounsaturated
and polyunsaturated fatty acids found in walnuts. At the
highest concentration (100 μM), LA and ALA signifi-
cantly reduced SCD1 expression (- 58% and - 62%,
respectively) while the other fatty acids were ineffective
(Figure 1G). In contrast, b-carotene (100 nM to 100
μM), g-tocopherol (100 nM to 100 μM) and b-sitosterol
(150 nM to 10 μM) had no effect on SCD1 expression
in foam cells (data not shown). When THP-1 foam cells
were treated with different fatty acids, only ALA elicited
an increased level of cholesterol efflux (Figure 1H).
Walnut oil decreases SCD1 expression by activating FXR
in THP-1 MDFC
The regulation of SCD1 expression is due to a complex
transcriptional network, including the action of nuclear
receptors (NRs), which are targets of fatty acids and var-
ious nutrients. Walnut oil treatment significantly
increased ligand-dependent activation of human FXR,
LXR and PXR, whereas minimal effects were seen for
PPARa, b/δ, g and RXRa ( F i g u r e2 A ) .H o w e v e r ,w h e n
specific pharmacological agonists of these receptors were
examined in THP-1 foam cells, only the FXR agonist
GW4064 significantly reduced SCD1 mRNA and protein
(Figure 2B). In addition, GW4064 increased cholesterol
efflux in a dose-dependent manner in these cells (Figure
2C). When the FXR antagonist guggulsterone (GGS) was
co-administered with GW4064, walnut oil or ALA, their
effect on SCD-1 expression was abolished (Figure 2D).
Walnut oil and its predominant n-3 PUFA ALA signifi-
cantly increased FXR mRNA expression (Figure 2E). FXR
activation can result in an increased expression of its tar-
get gene, small heterodimer partner (SHP; Figure 2E),
which serves as a repressive transcription factor in the
regulation of down-stream gene expression. When SHP
was over-expressed in foam cells, SCD1 expression was
significantly reduced (Figure 2F).
Following walnut oil intake, human serum rich in ALA
significantly decreases SCD1 expression in THP-1 MDFC
Our in vitro data suggests that walnut oil and the n-3
PUFA ALA increases cholesterol efflux in foam cells.
The hypothesis tested herein was that bioactive mole-
cules are present in human serum following consump-
tion of walnuts that affect SCD1 expression and thus
have beneficial effects on cholesterol efflux. SCD1
mRNAs were reduced by all postprandial sera taken after
consumption of different walnut components with sera
of walnut oil group having the greatest SCD1 reduction
(Figure 3). The SCD1 lowering effect between walnut oil
and walnut skin groups was significantly different (P =
0.001). A significant time effect (P <0 . 0 0 1 )o nSCD1
expression was observed following the intake of all wal-
nut components with the maximal SCD1 reduction
being achieved 4 to 6 h postprandially (Figure 3). Serum
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Page 4 of 13Figure 1 Walnut oil affects cholesterol transport and storage in THP-1 macrophage-derived foam cells (MDFC). (A) Walnut oil increases
cholesterol efflux. DMSO treated cells have 2.3% cholesterol efflux (of total
3H-Ch). Values of DMSO treated cells are normalized and expressed
as 100%. (B) Expression change of genes related with cholesterol transport and storage following walnut oil treatment. Full names of all
abbreviation are as described in Table S1 footnote. (C) Walnut oil affects gene expression related with lipogenesis and fatty acid oxidation. (D)
Walnut oil treatment decreases SCD1 protein. Band intensities were determined by OptiQuant Image analysis software (Packard Instrument Co.,
Meriden, CT). (E) Effect of walnut oil on ABCA1 and ABCG1 protein levels. (F) Effect of SCD1 on cholesterol efflux. SCD1 overespression is shown
by western blot. A total of 60 μg proteins were loaded on each lane of control (empty plasmid) and overexpression groups. Bars not sharing
common letters (a, b or c) differ with P < 0.05. (G) Fatty acids affect SCD1 expression. Fatty acids are conjugated to BSA with a molar ratio of 4:1
modified from method described by Calder et al. [50]. PA: palmitic acid; OA: oleic acid; LA: linoleic acid; ALA: alpha linolenic acid. (H) Fatty acids
affect cholesterol efflux. Symbol * in all figure panels indicates a significant difference from respective control with P < 0.05. The data presented
are means ± SEM of triplicate wells of two independent experiments.
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tribution of individual fatty acids to the SCD1 change
observed in these cells (Table 1). Following walnut oil
intake, saturated fatty acids, myristic acid (14:0) and pal-
mitic acid (16:0), were significantly decreased by 25%
and 7%, respectively. Palmitoleic acid (16:1) and oleic
acid (18:1) MUFAs both were reduced significantly by
18% and 8%, respectively. Of the major n-6 PUFAs, LA
(18:2) was significantly increased (9%) in the postprandial
state while gamma-linolenic acid (g18:3) and arachidonic
acid (20:4) were decreased (9% and 6%, respectively).
Among the n-3 PUFAs evaluated, ALA (a18:3) was
Figure 2 Walnut oil inhibits SCD1 through a FXR pathway in THP-1 MDFC. (A) Activation of walnut oil on nuclear receptor ligand binding
domain of Dual Luciferase Reporter Assay. PPAR: peroxisome proliferator-activated receptor; LXR: liver-X-receptor; RXR: retinoic-X-receptor; PXR:
pregnane-X-receptor; FXR: farnesoid-X-receptor. (B) SCD1 protein (top) and mRNA (bottom) changes following nuclear receptor agonists
treatment. SCD1 protein change was detected by Western blot. Treatments are as follows: Lane 1: DMSO control; Lane 2: ciprofibrate 100 μM
(PPAR-a agonist); Lane 3: GW501506 500 nM (PPAR-b agonist); Lane 4: rosiglitazone 10 μM (PPAR-g agonist); Lane 5: TO901317 5 μM (LXR
agonist); Lane 6: 9-cis RA 100 nM (RXR agonist); Lane 7: rifamipicin 25 μM (PXR agonist); Lane 8: GW4064 10 μM (FXR agonist). (C) FXR activation
increases cholesterol efflux. (D) FXR activation decreases SCD1 expression. THP-1 MDFCs were treated with 10 μM GW4064 (FXR agonist), walnut
oil (0.5 mg/mL), 100 μM ALA in the presence or absence of 50 μM GGS (FXR antagonist). Bars not sharing common letters are significantly
different. (E) Walnut oil and ALA activate FXR and increase its target gene SHP expression. (F) Overexpression of SHP inhibits SCD1 expression in
MDFC. THP-1 derived macrophages were transfected with pCMX-hSHP and empty plasmid (control) for 24 h. Symbol * in all figure panels
indicates a significant difference from respective control (P < 0.05). The data presented are means ± SEM of triplicate wells of two independent
experiments.
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sumption of walnut oil. Changes in the other n-3 PUFA
were not statistically different between sera of baseline
and 4 h postprandially. In addition, total n-6 PUFA and
n-3 PUFA were increased significantly following walnut
oil intake. Specifically, walnut oil intake increased the
ratio of ALA/LA by 3-fold, compared with that of
baseline.
Categorized by basal CRP level, human sera have
different lipidemic responses to dietary interventions
Study participants were overweight with a mean BMI of
29.7 kg/m
2 (BMI = 30 kg/m
2 being obese). Five out of
fifteen subjects met at least two diagnostic criteria for
metabolic syndrome [21]. Multiple metabolic factors of
metabolic syndrome, including dyslipidemia, and proin-
flammatory state, appear to promote the development of
atherosclerotic cardiovascular disease [22]. Baseline and
postprandial serum lipid parameters (TG, TC, and LDL-
C) and inflammatory biomarkers (TNF-a;I L - 6 ,a n d
CRP) are presented in Table 2. Serum CRP from partici-
pants who consumed walnut oil ranged through 0.29
mg/L to 17.3 mg/L, with a median of 1.9 mg/L at base-
line. Using 2 mg/L CRP as an arbitrary cut point, parti-
cipants were categorized as low (8 subjects; a mean of
1.6 mg/L) or high (7 subjects; a mean of 5.6 mg/L) CRP
sub-groups. Despite a significant difference in CRP
levels between the two sub-groups, no time effect on
CRP change was observed postprandially (Figure 4A).
When data were pooled, serum TG peaked at 4h post-
prandially with a 26% increase following walnut oil
intake, compared to baseline. However, participants in
the high CRP sub-group had a significantly higher (36%)
postprandial TG response (calculated as area under the
curve, AUC), compared with participants in the low
CRP sub-group (Figure 4B). TC, LDL-C and HDL-C
changes were not significantly different between the two
CRP sub-groups (Figure 4C, 4D, 4E).
The benefits of walnut oil on cholesterol efflux are
evident in the low CRP sub-group
Serum effects on cholesterol efflux were examined by
comparing baseline sera and serum samples collected 4h
postprandially in the walnut oil group. The experimental
conditions were designed to mimic the in vivo response
of foam cells exposed to nutrient rich serum during the
postprandial state. Compared to non-sera treated cells,
both baseline and 4-hour postprandial sera treated cells
had significantly increased cholesterol efflux by 3 fold
and 3.3 fold, respectively (Figure 5A). However, the dif-
ference in efflux between baseline and potprandial sera
treated cells was not statistically significant. Interest-
ingly, re-analysis of the efflux data indicated that human
sera from the high and low CRP sub-groups had
Figure 3 Human serum affects SCD1 expression and
cholesterol efflux in THP-1 MDFC. Human serum affects SCD1
expression in THP-1 MDFCs. Samples were taken from 15 subjects
consuming different walnut components: whole walnut, walnut oil,
defatted walnut meat, and walnut skin. Baseline serum as well as
postprandial serum of 1, 2, 4, 6 h were applied as treatment (10%, v:
v) for 24 h in serum free media. Real time PCR value of individual
serum treated sample is divided by a PCR value of a pooled serum
treated sample to minimize the variation between PCR runs and to
exclude a non-specific serum effect on gene expression. Value of
each postprandial serum treated sample is adjusted by baseline
value, which served as a control within the same dietary period.
Data were logarithm transformed for analysis. Sera of fifteen
participants at baseline and 1, 2, 4, and 6 h postprandially were
applied as treatment. N = 75 of each dietary group.
Table 1 Serum fatty acid composition (as percentage of
total) of walnut oil group at baseline and 4 h
postprandially
Fatty acid Carbon: Time Change
profile Double-bond 0 h 4 h 4 h vs. 0 h
14:0 0.93 ± 0.12 0.7 ± 0.08 - 25%
‡
SFA 16:0 20.5 ± 0.72 19 ± 0.62 - 7.3%
‡
18:0 5.83 ± 0.28 5.77 ± 0.23 - 1%
16:1 2.14 ± 0.23 1.76 ± 0.22 - 17.8%
‡
MUFA 18:1 21 ± 0.64 19.5 ± 0.64 - 7.8%
‡
18:2 34.5 ± 1.37 37.58 ± 1.26 9%
†
PUFA g18:3 0.58 ± 0.04 0.53 ± 0.04 - 8.6%
†
(n-6) 20:4 8.2 ± 0.47 7.67 ± 0.43 - 6.3%
†
a18:3 0.74 ± 0.06 2.2 ± 0.16 197%
‡
PUFA 20:5 0.88 ± 0.15 0.83 ± 0.15 - 5.3%
(n-3) 22:5 0.55 ± 0.03 0.52 ± 0.03 - 5.5%
22:6 1.73 ± 0.16 1.67 ± 0.15 - 3.5%
Total n-6 44.88 ± 1.7 47.3 ± 1.52 5.4%
Total n-3 3.9 ± 0.34 5.1 ± 0.35 30.8%
‡
n-3/n-6 0.09 ± 0.01 0.11 ± 0.01 22.2%
†
a18:3/18:2 0.02 ± 0.002 0.06 ± 0.004 200%
‡
Values are expressed as mean (percentage of total fatty acid) ± SEM. MUFA:
monounsaturated fatty acid; PUFA: polyunsaturated fatty acid; 14:0 myristic
acid; 16:0 palmitic acid; 18:0 stearic acid; 16:1 palmitoleic acid; 18:1 oleic acid;
18:2 linoleic acid; g18:3 gamma-linolenic acid; 20:4 arachidonic acid; a18:3
alpha-linolenic acid; 20:5 eicosapentaenoic acid; 20:6 docosapentaenoic acid;
22:6 docosahexaenoic acid. Superscripts ‡: P < 0.001; †: 0.001 ≤ P < 0.01.
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Page 7 of 13Table 2 Serum lipid and inflammatory biomarker measurement of subjects in walnut oil group
Lipids Inflammatory markers
Time (h) TG
(mg/dL)
TC
(mg/dL)
LDL-C
(mg/dL)
HDL-C
(mg/dL)
TNF-a
(pg/mL)
IL-6
(pg/mL)
CRP
(mg/L)
0 129.5 (15.1) 197.4 (6.2) 130.5 (5.8) 41.1 (2.9) 1.46 (0.43) 1.28 (0.28) 3 (0.75)
1 136.7 (14.6) 210.2 (7.3) 140.3 (6.6) 42.7 (2.9) 2.05 (0.56) 1.29 (0.32) 3.93 (1.23)
2 158.9 (15.7)* 211 (6.5) 138 (5.2) 41.1 (3.3) 1.5 (0.27) 2.05 (0.54) 4.04 (1.07)
4 163.2 (19.5)* 207.3 (6.6) 134.4 (6.1) 40.3 (3.1) 2.14 (0.7) 1.95 (0.38) 3.25 (0.72)
6 133.3 (14.6) 206.3 (6.1) 138.8 (6.1) 40.9 (3.5) 1.95 (0.66) 2.47 (0.36) 3.38 (0.96)
TG: triacylglycerol; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TNF-a: tumor necrosis factor alpha;
IL-6: interleukin 6; CRP: C reactive protein. All values were expressed as mean ± SEM. Inflammatory biomarkers were measured by high sensitive ELISA. The GCRC
Core Laboratory at Hershey Medical Center performed the assays for lipids and lipoproteins. LDL-C was calculated using the Friedewald equation [51]. Symbol *
indicates a significant difference from baseline.
Figure 4 Categorized by baseline CRP level (2 mg/L as a cutting point), subjects have different serum lipid response following walnut
oil intake. (A) Changes in CRP between low- and high-CRP subgroups. CRP values were expressed as mean (mg/L) ± SEM. Subjects were
categorized as low (8 subjects) or high (7 subjects) CRP sub-groups based on the mean of baseline CRP values (P < 0.001 between sub-groups).
(B) Changes in TG between low- and high-CRP subgroups (P < 0.01 between sub-groups). (C) Changes inTC between low- and high-CRP
subgroups. (D) Changes in LDL-C between low- and high-CRP subgroups. (E) Changes in HDL-C between low- and high-CRP subgroups. Lipids
and lipoproteins were expressed as mean (mg/dL) ± SEM. Open square with dashed line represents the high CRP sub-group. Solid circle with
straight line represents the low CRP sub-group.
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Page 8 of 13different effects on cholesterol efflux. Sera from the low
CRP-subgroup increased cholesterol efflux by 17%, com-
pared to baseline serum treatment, while postprandial
sera from the high CRP sub-group did not significantly
change cholesterol efflux (Figure 5B). The marked
increase of cholesterol efflux following human sera
treatment is due to the existence of lipid acceptor HDL
in both the baseline and postprandial sera. To rule out
the possibility that the increased cholesterol efflux in
low CRP sub-group being the functionality change in
HDL lipoproteins, i.e. fatty acid enrichment in HDL,
HDL lipoprotein in the walnut oil group were isolated
f r o mt h ep l a s m aa n daf a t t ya c i da n a l y s i so ft h ep h o s -
pholipid fraction was performed. No significant differ-
ences were observed in fatty acids in the HDL
phospholipid fraction between baseline and postprandial
4h sera (Table 3).
Sera from the low CRP sub-group have more pronounced
SCD1 lowering effect without changing ABC transporters
in THP-1 foam cells
Our results suggest that the increased level of cholesterol
efflux between baseline and postprandial sera from low
CRP sub-group was unlikely due to the HDL difference
in either concentration (Figure 4E) or composition (Table
3). SCD1, another key regulator in cholesterol efflux as
s h o w ni no u rin vitro study, could be significantly
affected following sera treatment. Sera from the low CRP
sub-group consuming walnut oil did significantly reduce
SCD1 mRNA expression by 41% and 39%, respectively, at
4 and 6 h postprandially (Figure 6A). There was only a
maximum of a 19% reduction in SCD1 expression by
sera from subjects in the high CRP sub-group, compared
to baseline (Figure 6A). Following walnut oil intake, post-
prandial sera (collected at 4 h) from the low CRP sub-
group significantly reduced SCD1 protein level by 30%,
compared with that of high CRP sub-group (Figure 6B).
In macrophages, the membrane transporters ABCA1 and
ABCG1 are the two major ATP binding cassette (ABC)
membrane proteins that facilitate cholesterol export
[23,24]. Changes in these two transporters could also
significantly affect the efficiency of cholesterol efflux.
Figure 5 Human sera of low and high CRP sub-groups
differentially affect cholesterol efflux. (A) Sera of subjects
consuming walnut oil affect cholesterol efflux. Following the
induction of foam cells, human sera (10%, v:v) of baseline and 4 h
postprandially were applied as treatment to induce cholesterol
efflux for 24 h. Following efflux period, control cells (incubated in
serum-free culture medium only) had a cholesterol efflux of 5.4%.
The value is normalized and expressed as 100%. (B) Categorized by
baseline CRP (cut point of 2 mg/L), changes of cholesterol efflux
following treatment by human sera of walnut oil group. Experiment
conditions were as described in Figure 3B. Symbol * indicates a
significant difference between control and treatment groups (P <
0.05). Results are representative of two independent experiments
with a duplicate at each time point (baseline and 4 h
postprandially) of each subject.
Table 3 Fatty acid composition (as percentage of total) of
HDL phospholipid fraction of walnut oil group at
baseline and 4 h postprandially
Fatty acid Carbon: Time
profile Double-bond 0 h 4 h P value
16:0 19.6 ± 1.35 20.5 ± 1.4 0.72
SFA 18:0 21.7 ± 0.43 21.8 ± 0.38 0.85
16:1 0.17 ± 0.05 0.11 ± 0.06 0.48
MUFA 18:1 9.91 ± 0.46 9.8 ± 0.51 0.86
18:2 23.4 ± 1.13 23.9 ± 1.1 0.74
PUFA g18:3 0.1 ± 0.02 0.11 ± 0.03 0.94
(n-6) 20:4 21.9 ± 1.18 21.7 ± 1.0 0.89
a18:3 0.21 ± 0.02 0.25 ± 0.02 0.15
PUFA 20:5 1.89 ± 0.43 1.88 ± 0.42 0.98
(n-3) 22:5 2.08 ± 0.17 1.97 ± 0.14 0.63
22:6 6.47 ± 0.63 6.41 ± 0.6 0.95
Total n-6 51.6 ± 0.9 51.8 ± 0.84 0.85
Total n-3 8.97 ± 0.76 8.85 ± 0.68 0.91
n-3/n-6 0.18 ± 0.02 0.17 ± 0.02 0.88
a18:3/18:2 0.009 ± 0.001 0.01 ± 0.001 0.2
Values are expressed as mean (percentage of total fatty acid) ± SEM.
Abbreviations are as designated in Table 1 footnote.
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Page 9 of 13Compared to baseline serum treatment, ABCA1 mRNA
was reduced following postprandial serum treatment of
the high CRP sub-group (Figure 6C). The decreased
response of ABCA1 was significantly different from that
of the low CRP sub-group. However, ABCA1 protein
level was not significantly changed following walnut oil
intake (Figure 6D). ABCG1 mRNA and protein were not
significantly reduced following postprandial serum treat-
ment and the change was not different between the two
CRP sub-groups (data not shown).
In the current study, lipid extracts from walnuts sig-
nificantly increased cholesterol efflux in foam cells. The
findings (Figure 1) suggest that the inhibition of SCD1
by ALA plays a critical role during this process. The
results are consistent with several previously published
reports, showing that long chain n-3 PUFAs treatment
led to an increased level of cholesterol efflux [25-28].
The presence of PUFAs, especially n-3 PUFAs facilitates
the free cholesterol movement and incorporation to
inner leaflet of plasma membrane [29]. Furthermore,
studies have shown that PUFAs can increase membrane
fluidity and permeability [30,31], and alter transbilayer
sterol localization, resulting in movement of membrane
sterols from cytofacial (inner) to exofacial (outer) leaflets
[32]. Therefore, ALA-elicited SCD1 inhibition will make
free cholesterol more available for the subsequent export
across plasma membrane. In addition, over-expression
of SCD1 resulted in a decrease in the cholesterol rich
region of the membrane [8]. Addition of walnut oil does
not restore the cholesterol efflux in the cells over-
expressing SCD1 in our study; it is partially due to the
non-synergistic activation of the SCD1promoter by var-
ious bioactive components in walnut oil. This also may
support regulation of SCD1 expression being important
to walnut oil’s ability to affect cholesterol efflux. Several
studies [33-36] indicated that PUFA could decrease cho-
lesterol efflux, possibly through degradation of ABCA1
via protein kinase C delta pathway [37]. In the present
study, walnut oil treatment did not result in significant
changes in ABC transporter proteins. Our previous
Figure 6 Human sera of low and high CRP sub-groups differentially affect gene expression.( A )C h a n g e si nSCD1 mRNA expression
following treatment of human sera from subjects consuming walnut oil. * indicates significant difference from baseline and between CRP sub-
groups (P < 0.01). (B) Quantification of SCD1 protein. Value of baseline sera treated cells of low CRP sub-group was normalized as 100. Bars not
sharing the same letters differ (P < 0.05). (C) Changes in membrane transporters ABCA1 mRNA following human sera treatment. (D) Changes in
ABCA1 proteins categorized by baseline CRP level. In the GLM model, age, gender, BMI, and glucose are served as covariates and ID number as
dummy variable.
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Page 10 of 13study also showed that ALA increased cholesterol efflux
without affecting membrane ABC proteins in macro-
phage-derived foam cells [4]. Knocking down SCD1
through siRNA reproduced the increased cholesterol
efflux without changing ABC transporters in foam cells
[4]. Thus, the increased cholesterol efflux induced by
walnut oil is unlikely due to the regulation of membrane
ABC transporters.
Lipid extracts from walnut components significantly
activated FXR to a greater extent than other tested
nuclear receptors. FXR plays a critically important role
in bile acid synthesis, secretion and re-absorption, and is
expressed at a high level in liver and intestine. Gene
knockout studies demonstrated an unexpected role for
FXR in lipid metabolism, where activation results in
hypolipidemia [38]. However, a direct effect of FXR on
atherosclerosis is still controversial [39-41]. Our in vitro
studies presented herein demonstrate that walnut oil,
especially its PUFA fraction increases cholesterol efflux.
This effect is mediated by a decrease of SCD1 through
activation of FXR pathway. This suggests that the action
of FXR in our model is atheroprotective.
To extrapolate the in vitro findings to humans, serum
samples taken from subjects consuming different walnut
components were applied as a treatment to cultured
THP-1 foam cells. Sera from individuals consuming wal-
nut components (whole walnut, oil, walnut skin and
defatted walnut meat) all decreased SCD1 expression in
THP-1 foam cells. There was a greater reduction in
SCD1 expression in serum samples from the walnut oil
group versus the whole walnut group. This could, in part,
be due to a different absorption rate that relates to the
physical form of the food [42]. Compared to whole wal-
nuts, walnut oil would have a faster absorption rate that
would result in a greater effect on gene regulation. Wal-
nut skins are higher in antioxidants (23 mmol/100 g),
compared to most other commonly consumed tree nuts
[43]. Chen et al found that flavonoids and polyphenolics
from almond skin extracts enhanced the resistance of
LDL to copper-induced oxidation both in vitro and
in vivo [44]. This suggests that walnut skins decreased
SCD1 expression by regulating oxidative products genera-
tion and release into the circulation. However, it still is
not clear what the exact mechanisms are for SCD1 lower-
ing following defatted walnut meat intake.
The postprandial sera-induced cholesterol efflux is unli-
k e l yd u et oaf u n c t i o n a l i t yc h a n g ei nH D Ls i n c et h e r e
was no change in HDL concentration or relative fatty
acid composition change in this fraction between baseline
and the postprandial time points or between the low or
high CRP sub-groups. In contrast, a three-fold increase of
ALA in the total lipid extract of sera was observed fol-
lowing walnut oil intake. In the postprandial state, the
increased level of ALA is presumably in triglyceride rich
lipoproteins, such as VLDL or chylomicrons rather than
HDL particles. The influx of nutrients from the GI tract
will markedly increase lipoprotein lipase activity, which
will release free fatty acid into the blood stream. These
newly released fatty acids, including ALA, could affect
cholesterol efflux in macrophages. Fatty acid enrichment
and lipid exchange between HDL and other lipoproteins
typically are regulated by lecithin-cholesterol acyltransfer-
ase (LCAT) and cholesteryl ester transfer protein (CETP).
A 6-hour observation period may not have been sufficient
to achieve the maximal LCAT and CETP activities or
obtain the maximal enrichment of ALA in HDL to
induce cholesterol efflux. Thus, long-term feeding studies
are needed to evaluate the effects of walnuts on HDL
functionality changes.
In our study, sera from subjects consuming walnuts
decreased SCD1 expression and increased cholesterol
efflux. Dyslipidemia and systemic inflammation are
major risk factors leading to cardiac events and exacer-
bating atherosclerosis development and progression. A
higher CRP level is a marker of a pro-inflammatory
state and is highly correlated with increased risks of
metabolic syndrome and cardiovascular diseases [22].
Results from several studies demonstrated that an ele-
vated inflammatory state, such as increased levels of
CRP [45], TNF-a and IL-1b [46,47] impairs cholesterol
efflux. Furthermore, inflammatory mediators increase
SCD1 activity in mouse macrophages [48] and in a long-
itudinal study in humans [49]. In the present study,
although SCD1 mRNA was slightly decreased by serum
from the high CRP sub-group, this did not translate into
any significant improvement in efflux presumably due to
the higher levels of circulating inflammatory mediators.
Conclusion
The studies presented herein demonstrated that lipid-
rich walnut oil significantly reduced SCD1 expression as
well as increased cholesterol efflux in macrophage-
derived foam cells, which will be of benefit for athero-
sclerosis regression.
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